Research Use Only
This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
PT-141 (Bremelanotide)
Skin, Hair & AestheticsFDA ApprovedAlso known as: Bremelanotide
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors (Viagra), PT-141 acts centrally through the nervous system rather than peripherally on blood flow, making it the first approved drug to target sexual desire rather than sexual performance..
Overview
Key Takeaways
- βSexual desire enhancement
- βHSDD treatment
- βErectile dysfunction (central mechanism)
- βHalf-life: ~2 hours
At A Glance
PT-141 selectively activates MC4R in the medial preoptic area and paraventricular nucleus of the hypothalamus, stimulating dopaminergic and oxytocinergic pathways that mediate sexual arousal and desire. This central mechanism explains its unique ability to increase subjective sexual desire rather than just enabling erectile function. It also has moderate affinity for MC3R and MC1R, though sexual effects are primarily MC4R-mediated.
PT-141 selectively activates MC4R in the medial preoptic area and paraventricular nucleus of the hypothalamus, stimulating dopaminergic and oxytocinergic pathways that mediate sexual arousal and desire. This central mechanism explains its unique ability to increase subjective sexual desire rather than just enabling erectile function. It also has moderate affinity for MC3R and MC1R, though sexual effects are primarily MC4R-mediated.
Overview
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors (Viagra), PT-141 acts centrally through the nervous system rather than peripherally on blood flow, making it the first approved drug to target sexual desire rather than sexual performance.
Potential Benefits
Potential Research Fields
Chemical Information
IUPAC Name
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
CAS Number
189691-06-3
Molecular Formula
C50H68N14O10
Molecular Mass
1025.18 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction Matrix
Contraindications
Uncontrolled hypertension. Cardiovascular disease. Concurrent use of PDE5 inhibitors (Viagra/Cialis) β risk of hypotension. Pregnancy or breastfeeding.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$29.99
up to $60.00
$3.9990
4
5
strip, vial, nasal_spray
Price History
2 data pointsVendors Selling PT-141 (Bremelanotide)
Research Score
40 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
4
Verified COAs
1
Vendors w/ COA
Latest test: 3/1/2026
Research Credibility
Quick Facts
Half-Life
~2 hours
Molecular Weight
1025.18 g/mol
Administration
Subcutaneous
CAS Number
189691-06-3
Trial Phase
FDA Approved
Safety Profile
Low RiskCommon Side Effects
- β’ Nausea
- β’ Flushing
- β’ Headache
- β’ Injection site reactions
Stop Use If
- Uncontrolled hypertension
- Cardiovascular disease
- Taking naltrexone
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is PT-141 (Bremelanotide) used for in research?
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors (Viagra), PT-141 acts centrally through the nervous system rather than peripherally on blood flow, making it the first approved drug to target sexual desire rather than sexual performance.
What forms does PT-141 (Bremelanotide) come in?
PT-141 (Bremelanotide) is available in strip, vial, nasal_spray forms.
How much does PT-141 (Bremelanotide) cost?
Prices start at $29.99 across 4 verified vendors.
How do I compare PT-141 (Bremelanotide) vendors?
Compare prices, payment methods, shipping, and COA scores across 4 vendors.